The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study

Little information exists regarding the epidemiology of the chronic bronchitis phenotype in unselected chronic obstructive pulmonary disease (COPD) populations. We examined the prevalence of the chronic bronchitis phenotype in COPD and non-COPD subjects from the PLATINO study, and investigated how it is associated with important outcomes. Post-bronchodilator forced expiratory volume in 1 s/forced vital capacity <0.70 was used to define COPD. Chronic bronchitis was defined as phlegm on most days, at least 3 months per year for ≥2 yrs. We also analysed another definition: cough and phlegm on most days, at least 3 months per year for ≥2 yrs. Spirometry was performed in 5,314 subjects (759 with and 4,554 without COPD). The proportion of subjects with and without COPD with chronic bronchitis defined as phlegm on most days, at least 3 months per year for ≥2 yrs was 14.4 and 6.2%, respectively. Using the other definition the prevalence was lower: 7.4% with and 2.5% without COPD. Among subjects with COPD, those with chronic bronchitis had worse lung function and general health status, and had more respiratory symptoms, physical activity limitation and exacerbations. Our study helps to understand the prevalence of the chronic bronchitis phenotype in an unselected COPD population at a particular time-point and suggests that chronic bronchitis in COPD is possibly associated with worse outcomes.

[1]  J. Hokanson,et al.  The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. , 2011, Chest.

[2]  Jiachun Lu,et al.  Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China , 2010, Respirology.

[3]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[4]  A. Menezes,et al.  Health status perception and airflow obstruction in five Latin American cities: the PLATINO study. , 2009, Respiratory medicine.

[5]  N. Roche,et al.  [Chronic bronchitis: prevalence and quality of life. Analysis of data from the French Health Interview Survey 2002-2003]. , 2009, Revue des maladies respiratoires.

[6]  S. Guerra,et al.  Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk , 2009, Thorax.

[7]  A. Menezes,et al.  Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. , 2009, Chest.

[8]  Nicolas Roche,et al.  Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.

[9]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[10]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[11]  P. Nilsson,et al.  Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis , 2005, Respiratory research.

[12]  A. Lindberg,et al.  Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. , 2005, Chest.

[13]  R. Stockley,et al.  The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). , 2002, Chest.

[14]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[15]  M. Miravitlles,et al.  Factors Associated with Increased Risk of Exacerbation and Hospital Admission in a Cohort of Ambulatory COPD Patients: A Multiple Logistic Regression Analysis , 2000, Respiration.

[16]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[17]  L. Fabbri,et al.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. , 1996, Thorax.

[18]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[19]  A. Menezes,et al.  Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study. , 1994, Thorax.

[20]  D. Dockery,et al.  Longitudinal lung function decline in subjects with respiratory symptoms. , 1992, The American review of respiratory disease.

[21]  P. Schnohr,et al.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. , 1990, Thorax.

[22]  D. Dockery,et al.  Chronic obstructive pulmonary disease mortality in six U.S. cities. , 1989, The American review of respiratory disease.

[23]  J Nyboe,et al.  Chronic obstructive lung disease in Copenhagen: cross‐sectional epidemiological aspects , 1989, Journal of internal medicine.

[24]  A. Buist,et al.  Respiratory symptoms, lung function, and mortality in a screening center cohort. , 1989, American journal of epidemiology.

[25]  Buist As Standardization of spirometry. , 1987 .

[26]  F. Kauffmann,et al.  Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. , 1986, The American review of respiratory disease.

[27]  D. Jarvis,et al.  Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. , 2007, American journal of respiratory and critical care medicine.

[28]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[29]  E. Hnizdo,et al.  Relevance of airflow obstruction and mucus hypersecretion to mortality. , 1991, Respiratory medicine.